Abstract
Repifermin (truncated, recombinant human keratinocyte growth factor-2, KGF-2) was evaluated in cynomolgus monkeys and healthy humans during a phase 1 trial. Monkeys received vehicle or repifermin at 20, 75, or 200 μg/kg IV or 750 μg/kg subcutaneous (SC) daily for 29 days. Clinical observations were made during the entire dosing period. Gross and microscopic changes were assessed at necropsy. Pharmacokinetic parameters and immunogenicity were evaluated in these monkeys and in humans, following a single or 7 daily IV bolus injections of 1, 5, 25, or 50 μg/kg repifermin. In monkeys, repifermin was well tolerated, and histologic evaluation demonstrated dose-dependent, reversible thickening of the mucosa throughout the alimentary tract, except for the stomach. In the alimentary tract tissues, nonepithelial tissues were not affected, indicating a specificity of repifermin for epithelial cells. Pharmacokinetics in both monkeys and humans were dose proportional, showed lack of drug accumulation with repeated daily dosing, and were characterized by high volumes of distribution and clearance rates, indicating substantial tissue binding and metabolism. Repifermin was not markedly immunogenic following multiple daily IV injections in either species. Serum repifermin concentrations in humans were comparable to those attained in monkeys that produced significant pharmacological effects on epithelial cells in the alimentary tract. These findings provide additional support for the ongoing clinical development of repifermin for diseases involving epithelial injury.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ruben SM, Jimenez P, Duan DR, et al. Keratinocyte growth factor-2. US patent 6 077 692. June 20, 2000.
Igarashi M, Finch PW, Aaronson SA. Characterization of recombinant human fibroblast growth factor (FGF-10) reveals functional similarities with keratinocyte growth factor (FGF-7). J Biol Chem. 1998;273:13230–13235.
Beer HD, Florence C, Dammeier J, McGuire L, Werner S, Duan DR. Mouse fibroblast growth factor-10: cDNA cloning, protein characterization, and regulation of mRNA expression. Oncogene. 1997;15:2211–2218.
Yamasaki M, Miyake A, Tagashira S, Itoh N. Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family. J Biol Chem. 1996;271:15918–15921.
Emoto H, Tagashira S, Mattei M-G, et al. Structure and expression of human fibroblast growth factor-10. J Biol Chem. 1997;272:23191–23194.
Finch PW, Rubin JS, Miki T, Ron D, Aaronson SA. Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science. 1989;245:752–755.
Martin GR. The roles of FGFs in the early development of vertebrate limbs. Genes Dev. 1998;12:1571–1586.
Bellusci S, Grindley J, Emoto H, Itoh N, Hogan BLM. Fibroblast growth factor 10 (FGF-10) and branching morphogenesis in the embryonic mouse lung. Development. 1997;124:4867–4878.
Sekine K, Ohuchi H, Fujiwara M, et al. FGF-10 is essential for limb and lung formation. Nat Genet. 1999;21:138–141.
Jimenez PA, Greenwalt D, Mendrick DL, et al. Keratinocyte growth factor-2. In: Narula SK, Coffman R, eds. New Cytokines as Potential Drugs. Basel, Switzerland: Birkh er Verlag; 2000:101–119.
Goldfarb M. Functions of fibroblast growth factors in vertebrate development. Cytokine Growth Factor Rev. 1996;7:311–325.
Miceli R, Hubert M, Santiago G, et al. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J Pharmacol Exper Ther. 1999;290:464–471.
Han DS, Li F, Holt L, et al. Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. Am J Physiol Gastrointest Liver Physiol. 2000;279:G1011-G1022.
Soler PM, Wright TE, Smith PD, et al. In vivo characterization of keratinocyte growth factor-2 as a potential wound healing agent. Wound Rep Reg. 1999;7:172–178.
Sonis ST. Oral complications (of mucositis). In: Holland JF, Bast RC Jr, Morton DL, Frei E III, Kufe DW, Weichselbaum RR, eds. Cancer Medicine. Baltimore, MD: Williams and Wilkins; 1997:3255–3264.
Institute of Laboratory Animal Resources Commission on Life Sciences; National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996.
Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res. 1991;8:1351–1359.
Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey, and man. Cancer Chemother Rep. 1966;50:219–244.
Stein KE. Immunogenicity of recombinant proteins. Proceedings of Preclinical and Clinical Development of Biological Therapeutics. Annapolis, MD: Center for Drug Development Science. October 17–19. 1999.
Schaer GL, Fink MP, Chernow B, Ahmed S, Parrillo JE. Renal hemodynamics and prostaglandin E2 excretion in a nonhuman primate model of septic shock. Crit Care Med. 1990;18:52–59.
Levine RR. Pharmacology: Drug Actions and Reactions, 4th ed. Boston: Little, Brown, and Co; 1990;110.
Mashimo H, Wu D-C, Podolsky DK, Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal Trefoil factor. Science. 1996;274:262–265.
Marchese C, Mancini P, Belleudi F. Receptor-mediated endocytosis of keratinocyte growth factor. J Cell Sci. 1998;111:3571–3527.
Author information
Authors and Affiliations
Corresponding author
Additional information
Published: April 25, 2002
Rights and permissions
About this article
Cite this article
Sung, C., Parry, T.J., Riccobene, T.A. et al. Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans. AAPS PharmSci 4, 8 (2002). https://doi.org/10.1208/ps040206
Received:
Published:
DOI: https://doi.org/10.1208/ps040206